A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT ID: NCT05239728
Last Updated: 2025-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
1800 participants
INTERVENTIONAL
2022-03-15
2029-09-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
NCT04489771
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
NCT03634540
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
NCT05468697
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
NCT04846920
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
NCT05030506
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Belzutifan + Pembrolizumab
Participants receive belzutifan 120 mg orally once daily (QD) for up to approximately 54 weeks PLUS pembrolizumab 400 mg via intravenous (IV) infusion once every 6 weeks (Q6W) for up to 9 administrations (up to approximately 54 weeks).
Belzutifan
Three 40 mg tablets given as a single oral 120 mg dose.
Pembrolizumab
400 mg via IV infusion
Placebo + Pembrolizumab
Participants receive placebo orally QD for up to approximately 54 weeks PLUS pembrolizumab 400 mg via IV infusion once Q6W for up to 9 administrations (up to approximately 54 weeks).
Pembrolizumab
400 mg via IV infusion
Placebo
Oral tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belzutifan
Three 40 mg tablets given as a single oral 120 mg dose.
Pembrolizumab
400 mg via IV infusion
Placebo
Oral tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has intermediate-high risk, high risk, or M1 no evidence of disease (NED) RCC as defined by the following pathological tumor-node metastasis and tumor grading:
1. Intermediate-high risk RCC: pT2, Grade 4 or sarcomatoid, N0, M0; pT3, any grade, N0, M0
2. High risk RCC: pT4, any Grade N0, M0; pT any stage, any Grade, N+, M0
3. M1 NED RCC participants who present not only with the primary kidney tumor but also solid, isolated, soft tissue metastases that can be completely resected at one of the following: the time of nephrectomy (synchronous) or, ≤2 years from nephrectomy (metachronous)
* Has undergone complete resection of the primary tumor (partial or radical nephrectomy) and complete resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED participants
* Must have undergone a nephrectomy and/or metastasectomy ≤12 weeks prior to randomization
* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 10 days before randomization.
* Male participants must agree to continue contraception at least 7 days after the last dose of belzutifan/placebo
* Female participants of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of pembrolizumab or at least 30 days after last dose of belzutifan/placebo, whichever occurs last
* Has adequate organ function
Exclusion Criteria
* Has a pulse oximeter reading \<92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
* Has clinically significant cardiovascular disease within 6 months from first dose of study intervention
* Has other clinically significant disorders such as: serious active nonhealing wound/ulcer/bone fracture; requirement for hemodialysis or peritoneal dialysis
* Has preexisting brain or bone metastatic lesions
* Has received prior systemic therapy for RCC
* Has received prior radiotherapy for RCC
* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention; administration of killed vaccines are allowed
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
* Has a known additional malignancy (other than RCC treated with nephrectomy and/or metastasectomy) that is progressing or has required active treatment within the past 3 years
* Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs); replacement therapy is allowed
* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Has an active infection, requiring systemic therapy
* Has a known history of human immunodeficiency virus (HIV) infection, a known history of Hepatitis B or known active Hepatitis C virus infection
* Has had an allogenic tissue/solid organ transplant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Arizona - Phoenix ( Site 3554)
Phoenix, Arizona, United States
City of Hope Comprehensive Cancer Center ( Site 3567)
Duarte, California, United States
Moores Cancer Center-Clinical Trials Office- Genitourinary ( Site 3516)
La Jolla, California, United States
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 3520)
Los Angeles, California, United States
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3518)
Orange, California, United States
Stanford Cancer Center ( Site 3523)
Palo Alto, California, United States
University of Colorado Anschutz Medical Campus ( Site 3514)
Aurora, Colorado, United States
Intermountain Health St. Mary's Regional Hospital ( Site 3562)
Grand Junction, Colorado, United States
Georgetown University Medical Center ( Site 3534)
Washington D.C., District of Columbia, United States
University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services ( Site 3517)
Miami, Florida, United States
Moffitt Cancer Center ( Site 3540)
Tampa, Florida, United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 3515)
Marietta, Georgia, United States
Parkview Research Center at Parkview Regional Medical Center ( Site 3526)
Fort Wayne, Indiana, United States
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center- GU Oncology ( Site 3549)
Baltimore, Maryland, United States
Massachusetts General Hospital ( Site 3571)
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 3572)
Boston, Massachusetts, United States
Dana-Farber Cancer Institute-GU ( Site 3505)
Boston, Massachusetts, United States
Cancer and Hematology Centers of Western Michigan ( Site 3502)
Grand Rapids, Michigan, United States
Washington University-Internal Medicine/Oncology ( Site 3531)
St Louis, Missouri, United States
St. Vincent Frontier Cancer Center-Research ( Site 3506)
Billings, Montana, United States
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 3550)
Omaha, Nebraska, United States
Englewood Hospital and Medical Center ( Site 3557)
Englewood, New Jersey, United States
Rutgers Cancer Institute of New Jersey ( Site 3541)
New Brunswick, New Jersey, United States
Monter Cancer Center ( Site 3560)
Lake Success, New York, United States
Icahn School of Medicine at Mount Sinai ( Site 3539)
New York, New York, United States
Memorial Sloan Kettering Cancer Center ( Site 3568)
New York, New York, United States
University of Rochester Medical Center ( Site 3528)
Rochester, New York, United States
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 3507)
Columbus, Ohio, United States
MidLantic urology ( Site 3501)
Bala-Cynwyd, Pennsylvania, United States
Fox Chase Cancer Center-GU Oncology ( Site 3535)
Philadelphia, Pennsylvania, United States
Sanford Cancer Center ( Site 3551)
Sioux Falls, South Dakota, United States
The West Clinic, PLLC dba West Cancer Center ( Site 3522)
Germantown, Tennessee, United States
Urology Associates ( Site 3512)
Nashville, Tennessee, United States
UT Southwestern Medical Center ( Site 3529)
Dallas, Texas, United States
University of Texas MD Anderson Cancer Center-Urology ( Site 3569)
Houston, Texas, United States
Inova Schar Cancer Institute ( Site 3525)
Fairfax, Virginia, United States
Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 3524)
Seattle, Washington, United States
Blacktown Hospital ( Site 0002)
Blacktown, New South Wales, Australia
Macquarie University-MQ Health Clinical Trials Unit ( Site 0003)
Macquarie University, New South Wales, Australia
Tamworth Hospital-North West Cancer Centre ( Site 0006)
North Tamworth, New South Wales, Australia
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 0001)
Brisbane, Queensland, Australia
Lyell McEwin Hospital-Oncology Clinical Trials Unit ( Site 0008)
Elizabeth Vale, South Australia, Australia
Austin Health-Cancer Clinical Trials Centre ( Site 0005)
Heidelberg, Victoria, Australia
Fiona Stanley Hospital-Medical Oncology ( Site 0004)
Murdoch, Western Australia, Australia
Hospital São Carlos-Oncocentro Ce ( Site 0104)
Fortaleza, Ceará, Brazil
Centro Avançado de Tratamento Oncológico- CENANTRON-Clinical Research ( Site 0105)
Belo Horizonte, Minas Gerais, Brazil
Instituto do Câncer e Transplante de Curitiba ( Site 0102)
Curitiba, Paraná, Brazil
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0103)
Natal, Rio Grande do Norte, Brazil
Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0101)
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas de Ribeirão Preto ( Site 0112)
Ribeirão Preto, São Paulo, Brazil
BP - A Beneficencia Portuguesa de São Paulo ( Site 0111)
São Paulo, , Brazil
MBAL Uni Hospital-Department of Medical Oncology ( Site 0204)
Panagyurishte, Pazardzhik, Bulgaria
MHAT Serdika-Second Department of Medical Oncology ( Site 0203)
Sofia, Sofia (stolitsa), Bulgaria
Complex Cancer Center Plovdiv-First Medical Oncology Department ( Site 0205)
Plovdiv, , Bulgaria
Arthur J.E. Child Comprehensive Cancer Centre ( Site 3706)
Calgary, Alberta, Canada
BC Cancer Vancouver-Clinical Trials Unit ( Site 3707)
Vancouver, British Columbia, Canada
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 3710)
Hamilton, Ontario, Canada
Victoria Hospital & Children's Hospital - London Health Scie-London Regional Cancer Program ( Site 3705)
London, Ontario, Canada
Princess Margaret Cancer Centre ( Site 3703)
Toronto, Ontario, Canada
CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 3708)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 3709)
Montreal, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 3701)
Québec, Quebec, Canada
Clínica Puerto Montt ( Site 0309)
Port Montt, Los Lagos Region, Chile
Oncocentro Valdivia ( Site 0312)
Valdivia, Los Ríos Region, Chile
FALP-UIDO ( Site 0302)
Santiago, Region M. de Santiago, Chile
Oncovida ( Site 0306)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0305)
Santiago, Region M. de Santiago, Chile
James Lind Centro de Investigacion del Cancer ( Site 0307)
Temuco, Región de la Araucanía, Chile
ONCOCENTRO APYS-ACEREY ( Site 0301)
Viña del Mar, Región de Valparaíso, Chile
Bradford Hill Norte ( Site 0303)
Antofagasta, , Chile
Afflilated Hospital of Bengbu Medical College-Urology Surgery ( Site 0438)
Bengbu, Anhui, China
Second Affiliated hospital of Anhui Medical University-Urology ( Site 0416)
Hefei, Anhui, China
Cancer Hospital Chinese Academy of Medical Science-Urinary Surgery ( Site 0435)
Beijing, Beijing Municipality, China
Beijing Cancer hospital-Urinary Surgery ( Site 0406)
Beijing, Beijing Municipality, China
First Medical Center of Chinese PLA General Hospital ( Site 0415)
Beijing, Beijing Municipality, China
Peking University First Hospital-Urology ( Site 0407)
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital ( Site 0414)
Chongqing, Chongqing Municipality, China
Army Medical Center of People's Liberation Army ( Site 0439)
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 0445)
Fuzhou, Fujian, China
The First Affiliated Hospital of Guangzhou Medical University ( Site 0403)
Guangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University-Urology Surgery ( Site 0402)
Guangzhou, Guangdong, China
SUN YAT-SEN UNIVERSITY CANCER CENTRE-Urology Surgery ( Site 0417)
Guangzhou, Guangdong, China
Henan Cancer Hospital-Urology ( Site 0441)
Zhengzhou, Henan, China
Tongji Hospital Tongji Medical,Science & Technology-oncology ( Site 0423)
Wuhan, Hubei, China
Wuhan Union Hospital ( Site 0430)
Wuhan, Hubei, China
Hubei Cancer Hospital-Urinary surgery ( Site 0419)
Wuhan, Hubei, China
Hunan Cancer Hospital ( Site 0421)
Changsha, Hunan, China
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( Site 0424)
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Nanchang University ( Site 0443)
Nanchang, Jiangxi, China
The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0432)
Nanchang, Jiangxi, China
The First Affiliated Hospital of Xi'an Jiaotong University ( Site 0431)
Xi'an, Shaanxi, China
Fudan University Shanghai Cancer Center-Urology department ( Site 0401)
Shanghai, Shanghai Municipality, China
Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 0418)
Shanghai, Shanghai Municipality, China
Huadong Hospital Affiliated to Fudan University ( Site 0405)
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University-Urology Surgery ( Site 0410)
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital ( Site 0422)
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital, Zhejiang University ( Site 0428)
Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital-Urology ( Site 0426)
Hangzhou, Zhejiang, China
Ningbo First Hospital-Urology ( Site 0433)
Ningbo, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 0425)
Wenzhou, Zhejiang, China
Clinica de la Costa S.A.S. ( Site 0506)
Barranquilla, Atlántico, Colombia
Administradora Country S.A. - Clinica del Country ( Site 0504)
Bogotá, Bogota D.C., Colombia
Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0505)
Valledupar, Cesar Department, Colombia
IMAT S.A.S ( Site 0501)
Montería, Departamento de Córdoba, Colombia
Fakultni Nemocnice u sv. Anny v Brne-Onkologicko-chirurgicke oddeleni ( Site 0603)
Brno, Brno-mesto, Czechia
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0605)
Brno, Brno-mesto, Czechia
Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0606)
Ostrava, Moravskoslezský kraj, Czechia
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0601)
Olomouc, Olomoucký kraj, Czechia
Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 0602)
Prague, Praha 4, Czechia
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0607)
Prague, Praha 5, Czechia
Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 0604)
Hradec Králové, , Czechia
Oulun yliopistollinen sairaala ( Site 0802)
Oulu, North Ostrobothnia, Finland
Kuopion Yliopistollinen Sairaala-Syöpäkeskus ( Site 0804)
Kuopio, Northern Savonia, Finland
Tampereen yliopistollinen sairaala ( Site 0805)
Tampere, Pirkanmaa, Finland
Turku University Hospital ( Site 0801)
Turku, Southwest Finland, Finland
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 0803)
Helsinki, Uusimaa, Finland
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 0903)
Strasbourg, Alsace, France
CENTRE LEON BERARD-Medical oncology ( Site 0902)
Lyon, Auvergne-Rhône-Alpes, France
ROC37 ( Site 0910)
Chambray-lès-Tours, Centre-Val de Loire, France
CHU Besançon-Medical oncology ( Site 0904)
Besançon, Doubs, France
Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou ( Site 0908)
Rennes, Ille-et-Vilaine, France
Centre Hospitalier Universitaire d'Angers-Urology ( Site 0901)
Angers, Maine-et-Loire, France
Hôpital Saint-Louis ( Site 0905)
Paris, , France
Hôpital Européen Georges Pompidou-Service d'Oncologie Médicale ( Site 0906)
Paris, , France
Gustave Roussy ( Site 0907)
Villejuif, Île-de-France Region, France
Hegau-Bodensee-Klinikum Singen ( Site 1016)
Singen, Baden-Wurttemberg, Germany
Universitaetsklinikum Tuebingen ( Site 1002)
Tübingen, Baden-Wurttemberg, Germany
klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 1003)
Munich, Bavaria, Germany
Universitätsklinikum Aachen ( Site 1024)
Aachen, North Rhine-Westphalia, Germany
Universitätsklinikum Bonn ( Site 1006)
Bonn, North Rhine-Westphalia, Germany
Universitaetsklinikum Duesseldorf ( Site 1017)
Düsseldorf, North Rhine-Westphalia, Germany
Universitaetsklinikum Essen ( Site 1004)
Essen, North Rhine-Westphalia, Germany
Universitätsklinikum Münster - Albert Schweitzer Campus ( Site 1005)
Münster, North Rhine-Westphalia, Germany
Universitaetsklinikum des Saarlandes-Klinik fuer Urologie und Kinderurologies ( Site 1020)
Homburg, Saarland, Germany
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Urologie ( Site 1021)
Dresden, Saxony, Germany
Krankenhaus Martha-Maria Halle-Dölau-Klinik für Urologie, Kinderurologie und urologische Onkologie ( Site 1008)
Halle, Saxony-Anhalt, Germany
SRH Wald-Klinikum Gera ( Site 1015)
Gera, Thuringia, Germany
Universitätsklinikum Jena ( Site 1007)
Jena, Thuringia, Germany
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1022)
Berlin, , Germany
Helios Klinikum Berlin-Buch ( Site 1011)
Berlin, , Germany
Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 1001)
Hamburg, , Germany
Alexandra Hospital-ONCOLOGY DEPT. ( Site 1102)
Athens, Attica, Greece
Metropolitan Hospital-2nd Oncology Dept ( Site 1104)
Athens, Attica, Greece
ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1101)
Chaïdári, Attica, Greece
Euromedica General Clinic Thessaloniki-Oncology Unit ( Site 1103)
Thessaloniki, , Greece
European Interbalkan Medical Center-Oncology Department ( Site 1105)
Thessaloniki, , Greece
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ ( Site 1319)
Szeged, Csongrád megye, Hungary
Petz Aladar Egyetemi Oktato Korhaz-Onkológiai Osztály ( Site 1321)
Győr, Győr-Moson-Sopron, Hungary
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 1316)
Budapest, Pest County, Hungary
Somogy Megyei Kaposi Mór Oktató Kórház-Oncology center ( Site 1311)
Kaposvár, Somogy County, Hungary
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 1310)
Debrecen, , Hungary
St. Vincent's University Hospital ( Site 1401)
Dublin, Dublin, Ireland
Tallaght University Hospital ( Site 1402)
Dublin, Dublin, Ireland
Cork University Hospital ( Site 1404)
Cork, , Ireland
Beaumont Hospital, Dublin-Cancer Clinical Trials & Research Unit ( Site 1403)
Dublin, , Ireland
Soroka Medical Center ( Site 1505)
Beersheba, , Israel
Rambam Health Care Campus-Oncology ( Site 1502)
Haifa, , Israel
Hadassah Medical Center-Oncology ( Site 1506)
Jerusalem, , Israel
Rabin Medical Center-Oncology ( Site 1503)
Petah Tikva, , Israel
Sheba Medical Center-ONCOLOGY ( Site 1504)
Ramat Gan, , Israel
Sourasky Medical Center-Oncology ( Site 1501)
Tel Aviv, , Israel
A.O.U.C. Policlinico di Bari ( Site 1607)
Bari, Apulia, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 1603)
Meldola, Emilia-Romagna, Italy
Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1604)
Rome, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1608)
Milan, Lombardy, Italy
Azienda Sanitaria Ospedaliera S Luigi Gonzaga-SCDU Oncologia Medica ( Site 1602)
Orbassano, Piedmont, Italy
Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1601)
Florence, Tuscany, Italy
Azienda USL 8 di Arezzo-Medical Oncology ( Site 1610)
Arezzo, , Italy
IRCCS - AOU di Bologna-Oncologia Medica Ardizzoni ( Site 1605)
Bologna, , Italy
Ospedale San Raffaele-Oncologia Medica ( Site 1606)
Milan, , Italy
Azienda Ospedaliera Santa Maria Terni-SC Oncologia ( Site 1609)
Terni, , Italy
Fujita Health University Hospital ( Site 1709)
Toyoake, Aichi-ken, Japan
National Cancer Center Hospital East ( Site 1704)
Kashiwa, Chiba, Japan
Toho University Sakura Medical Center ( Site 1718)
Sakura, Chiba, Japan
Ehime University Hospital ( Site 1714)
Tōon, Ehime, Japan
Sapporo Medical University Hospital ( Site 1702)
Sapporo, Hokkaido, Japan
Hokkaido University Hospital ( Site 1701)
Sapporo, Hokkaido, Japan
Kanagawa Cancer Center ( Site 1703)
Yokohama, Kanagawa, Japan
Nara Medical University Hospital ( Site 1712)
Kashihara, Nara, Japan
Bell Land General Hospital ( Site 1710)
Sakai, Osaka, Japan
The University of Osaka Hospital ( Site 1711)
Suita, Osaka, Japan
Hamamatsu University Hospital ( Site 1708)
Hamamatsu, Shizuoka, Japan
Toranomon Hospital ( Site 1706)
Minato-ku, Tokyo, Japan
Toyama University Hospital ( Site 1713)
Toyoma, Toyama, Japan
Kyushu University Hospital ( Site 1715)
Fukuoka, , Japan
Kagoshima University Hospital ( Site 1719)
Kagoshima, , Japan
Kumamoto University Hospital ( Site 1716)
Kumamoto, , Japan
Okayama University Hospital ( Site 1720)
Okayama, , Japan
Nippon Medical School Hospital ( Site 1705)
Tokyo, , Japan
Tokyo Women's Medical University Adachi Medical Center ( Site 1717)
Tokyo, , Japan
Keio University Hospital ( Site 1707)
Tokyo, , Japan
Wakayama Medical University Hospital ( Site 1721)
Wakayama, , Japan
University Malaya Medical Centre ( Site 1804)
Lembah Pantai, Kuala Lumpur, Malaysia
Hospital Pulau Pinang ( Site 1806)
George Town, Pulau Pinang, Malaysia
Sarawak General Hospital-Radiotherapy Unit ( Site 1805)
Kuching, Sarawak, Malaysia
Terapias Integrales del Riñon SA de CV ( Site 1910)
Guadalajara, Jalisco, Mexico
Hospital Civil Fray Antonio Alcalde-Oncology ( Site 1906)
Guadalajara, Jalisco, Mexico
BRCR Global Mexico - Guadalajara-Research ( Site 1908)
Guadalajara, Jalisco, Mexico
INSTITUTO NACIONAL DE CANCEROLOGIA ( Site 1902)
Mexico City, Mexico City, Mexico
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran-Oncologia y Hematologia ( Site 1912)
Mexico City, Mexico City, Mexico
Filios Alta Medicina ( Site 1903)
Monterrey, Nuevo León, Mexico
iCan Oncology Center Centro Medico AVE ( Site 1901)
Monterrey, Nuevo León, Mexico
Hospital H+ Queretaro-Cuidados Oncológicos ( Site 1905)
Querétaro City, Querétaro, Mexico
BRCR Global Mexico - Queretaro-SMIQ ( Site 1907)
Querétaro City, Querétaro, Mexico
Centro de Oncología Personalizada ( Site 1911)
Culiacán, Sinaloa, Mexico
Centro de Investigacion Clinica de Oaxaca ( Site 1904)
Oaxaca City, , Mexico
Oncocenter ( Site 1909)
Puebla City, , Mexico
Ziekenhuis Rijnstate-Rijnstate Centrum Oncologisch Onderzoek ( Site 3113)
Arnhem, Gelderland, Netherlands
Radboudumc ( Site 3120)
Nijmegen, Gelderland, Netherlands
Maastricht UMC+ ( Site 3104)
Maastricht, Limburg, Netherlands
Amphia Ziekenhuis, locatie Breda Molengracht ( Site 3103)
Breda, North Brabant, Netherlands
Maxima Medisch Centrum, locatie Eindhoven ( Site 3116)
Eindhoven, North Brabant, Netherlands
Amsterdam UMC, locatie AMC ( Site 3105)
Amsterdam, North Holland, Netherlands
Tergooiziekenhuizen, locatie Hilversum ( Site 3102)
Hilversum, North Holland, Netherlands
Spaarne Gasthuis - Hoofddorp-Oncology ( Site 3107)
Hoofddorp, North Holland, Netherlands
Isala, locatie Zwolle-Oncology ( Site 3111)
Zwolle, Overijssel, Netherlands
Haaglanden MC - locatie Antoniushove ( Site 3117)
Leidschendam, South Holland, Netherlands
Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 3101)
Schiedam, South Holland, Netherlands
Haga Ziekenhuis locatie Leyweg-Oncology ( Site 3108)
The Hague, South Holland, Netherlands
University Medical Center Groningen ( Site 3121)
Groningen, , Netherlands
St. Antonius Ziekenhuis, locatie Utrecht-Interne geneeskunde ( Site 3112)
Utrecht, , Netherlands
Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 3106)
Utrecht, , Netherlands
Auckland City Hospital ( Site 2003)
Auckland, , New Zealand
Przychodnia Lekarska KOMED ( Site 2304)
Konin, Greater Poland Voivodeship, Poland
Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-chemotherapy department ( Site 2312)
Poznan, Greater Poland Voivodeship, Poland
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2307)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
MICS Centrum Medyczne Torun ( Site 2305)
Torun, Kuyavian-Pomeranian Voivodeship, Poland
Szpital Wojewódzki im. Świętego Lukasza SP ZOZ w Tarnowie ( Site 2311)
Tarnów, Lesser Poland Voivodeship, Poland
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2313)
Siedlce, Masovian Voivodeship, Poland
Luxmed Onkologia sp. z o. o. ( Site 2303)
Warsaw, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2301)
Warsaw, Masovian Voivodeship, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 2306)
Przemyśl, Podkarpackie Voivodeship, Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 2309)
Wrocław, Silesian Voivodeship, Poland
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 2302)
Koszalin, West Pomeranian Voivodeship, Poland
Twoja Przychodnia - Szczecinskie Centrum Medyczne ( Site 2315)
Szczecin, West Pomeranian Voivodeship, Poland
Cardiomed SRL Cluj-Napoca ( Site 2406)
Cluj-Napoca, Cluj, Romania
Amethyst Radiotherapy Center-Oncologie Medicala ( Site 2405)
Florești, Cluj, Romania
Centrul de Oncologie Sfantul Nectarie-Medical ( Site 2401)
Craiova, Dolj, Romania
Radiology Therapeutic Center-Oncology ( Site 2404)
Otopeni, Ilfov, Romania
Cabinet Medical Oncomed ( Site 2403)
Timișoara, Timiș County, Romania
MEMORIAL HEALTHCARE INTERNATIONAL S.R.L ( Site 2407)
Bucharest, , Romania
National Cancer Centre Singapore ( Site 3601)
Singapore, Central Singapore, Singapore
National University Hospital ( Site 3602)
Singapore, South West, Singapore
National Cancer Center-Center for Urologic Cancer ( Site 2604)
Goyang-si, Kyonggi-do, South Korea
Seoul National University Bundang Hospital-Urology ( Site 2602)
Seongnam, Kyonggi-do, South Korea
Asan Medical Center-Oncology ( Site 2601)
Songpagu, Seoul, South Korea
Samsung Medical Center ( Site 2603)
Seoul, , South Korea
Institut Català d'Oncologia (ICO) - Girona ( Site 2707)
Girona, Gerona, Spain
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 2710)
Madrid, Madrid, Comunidad de, Spain
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 2708)
Madrid, Madrid, Comunidad de, Spain
Fundación Instituto Valenciano de Oncología ( Site 2705)
Valencia, Valenciana, Comunitat, Spain
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2702)
Barcelona, , Spain
Hospital Lucus Augusti-Oncology ( Site 2706)
Lugo, , Spain
Hospital Clinico San Carlos-Oncology Department ( Site 2703)
Madrid, , Spain
Hospital Universitario Virgen de la Victoria-Phase II-III-IV Trials ( Site 2709)
Málaga, , Spain
Karolinska Universitetssjukhuset Solna ( Site 2802)
Stockholm, Stockholm County, Sweden
Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 2803)
Uppsala, Uppsala County, Sweden
Sahlgrenska Universitetssjukhuset ( Site 2801)
Gothenburg, Västra Götaland County, Sweden
Chang Gung Memorial Hospital at Kaohsiung-Oncology and Hematology ( Site 2905)
Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan
Tri-Service General Hospital ( Site 2908)
Taipei City, Taipei, Taiwan
Kaohsiung Veterans General Hospital ( Site 2901)
Kaohsiung City, , Taiwan
China Medical University Hospital-Department of Urology ( Site 2907)
Taichung, , Taiwan
Taichung Veterans General Hospital ( Site 2902)
Taichung, , Taiwan
National Taiwan University Hospital ( Site 2904)
Taipei, , Taiwan
Taipei Veterans General Hospital ( Site 2903)
Taipei, , Taiwan
Chang Gung Medical Foundation-Linkou Branch-Urology ( Site 2906)
Taoyuan District, , Taiwan
Chulalongkorn University ( Site 3005)
Bangkok, Bangkok, Thailand
Ramathibodi Hospital ( Site 3001)
Bangkok, Bangkok, Thailand
Faculty of Medicine Siriraj Hospital ( Site 3002)
Bangkok, Bangkok, Thailand
Songklanagarind hospital ( Site 3004)
Hat Yai, Changwat Songkhla, Thailand
Istanbul Universitesi Cerrahpasa-Internal Diseases ( Site 3204)
Istanbul- Fatih, Istanbul, Turkey (Türkiye)
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 3208)
Adana, , Turkey (Türkiye)
Ankara Gülhane Eitim ve Aratrma Hastanesi-Oncology ( Site 3207)
Ankara, , Turkey (Türkiye)
Ankara University Hospital Cebeci ( Site 3209)
Ankara, , Turkey (Türkiye)
Hacettepe Universitesi-oncology hospital ( Site 3203)
Ankara, , Turkey (Türkiye)
Ankara Bilkent Şehir Hastanesi-oncology ( Site 3206)
Ankara, , Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3201)
Istanbul, , Turkey (Türkiye)
Ege University Medicine of Faculty-Medical Oncology ( Site 3202)
Izmir, , Turkey (Türkiye)
Royal Free Hospital ( Site 3304)
London, England, United Kingdom
The Christie NHS Foundation Trust ( Site 3301)
Manchester, England, United Kingdom
City Hospital, Nottingham University Hospitals ( Site 3303)
Nottingham, England, United Kingdom
Beatson West of Scotland Cancer Centre-Clinical Trials Unit ( Site 3305)
Glasgow, Glasgow City, United Kingdom
Charing Cross Hospital ( Site 3302)
London, Hammersmith and Fulham, United Kingdom
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 3307)
London, London, City of, United Kingdom
Singleton Hospital ( Site 3306)
Swansea, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-6482-022
Identifier Type: OTHER
Identifier Source: secondary_id
LITESPARK-022
Identifier Type: OTHER
Identifier Source: secondary_id
jRCT2051220030
Identifier Type: REGISTRY
Identifier Source: secondary_id
2023-505023-31-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1290-7346
Identifier Type: REGISTRY
Identifier Source: secondary_id
2021-003436-92
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
6482-022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.